California-based biotech company Omeat has launched its first pilot plant facility. This crucial milestone makes the company one step closer to finally entering the market. The 15,000-square-foot pilot plant is situated outside of Los Angeles, California, and ready to accommodate bioreactors up to 10,000L in size, giving it the capacity to produce up to 400 tons of cultivated meat annually.
“We now have an integrated, farm-to-table supply chain. Omeat’s process begins at our farm with the collection of plasma from Omeat’s herd of Holstein cows. The plasma is transported to the new pilot facility, where it’s used to derive Plenty, Omeat’s affordable and effective proprietary growth factor that replaces the need for Fetal Bovine Serum (FBS). Inside Omeat’s bioreactors, Plenty, and bovine cells are combined to produce Omeat ground beef. It’s a breakthrough process for making meat that is pure, delicious, and consistent.” - Jim Miller, Omeat’s Chief Technology Officer.
The biotech start-up was founded four years ago and entered the industry with a revolutionary approach to cultivated meat production - using collected cow plasma to avoid artificial growth factors, reducing the cost and complexity of cultured meat production.
“We continue to push the boundaries for cultivated meat and challenge existing processes. We’re pioneering a very unique farm-to-table approach that enables us to create delicious real meat with a fraction of the resources needed to produce conventional meat. It’s a more humane and sustainable way to satisfy the growing global appetite for meat. We remain confident that at scale, Omeat’s prices will be less than conventional meat, providing accessibility to high-quality protein worldwide.” - Omeat’s Founder and CEO, Ali Khademhosseini.
Image Credit: Omeat
ความคิดเห็น